Non-cystic Fibrosis Bronchiectasis Clinical Trial
Official title:
A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52 Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Non-Cystic Fibrosis Bronchiectasis (MAHALE)
This is a multicentre, randomised, double-blind, parallel-group, placebo-controlled, phase III study originally designed to test the hypothesis that benralizumab will reduce exacerbation rates compared with placebo on top of standard-of-care therapy in adult patients with non-cystic fibrosis bronchiectasis with eosinophilic inflammation (NCFB+EI). All patients who complete the double-blind treatment period (28 to 52 weeks depending on the timing of patient randomization and when the revised CSP version 3.0 becomes effective) on investigational product (IP) may be eligible to continue into an open-label extension (OLE) period during which all patients will receive benralizumab. The revised OLE period is intended to allow patients approximately 32 weeks of treatment with open label benralizumab (24 weeks followed by a FU visit 8 weeks after the last dose of IP for a total of approximately 32 weeks).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01792440 -
The Sputum Colour Chart as a Predictor of Lung Inflammation and Proteolysis in Non-cystic Fibrosis Bronchiectasis
|
N/A | |
Completed |
NCT05523180 -
A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life
|
N/A | |
Completed |
NCT03218917 -
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
|
Phase 2 | |
Completed |
NCT05495243 -
Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-CF Bronchiectasis With Excess Mucus and Cough
|
Phase 2 | |
Recruiting |
NCT06237348 -
Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH
|
N/A | |
Completed |
NCT03056326 -
A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT02614300 -
The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis
|
N/A | |
Recruiting |
NCT04322929 -
Roflumilast in Non-CF Bronchiectasis Study (2019)
|
Phase 2 | |
Completed |
NCT05369624 -
Exercise Capacity in Non-cystic Fibrosis Bronchiectasis After a Pulmonary Rehabilitation Home-based Program
|
N/A | |
Completed |
NCT04010799 -
A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
|
Phase 1 | |
Completed |
NCT03428334 -
Roflumilast in Non-CF Bronchiectasis Study
|
Phase 2 | |
Recruiting |
NCT06164470 -
Impact of Support Groups for Patients With Non-Cystic Fibrosis Bronchiectasis
|
N/A | |
Completed |
NCT04656275 -
A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation
|
Phase 1 | |
Not yet recruiting |
NCT06151366 -
Early Detection of Pulmonary Exacerbations in Non-cystic Fibrosis Bronchiectasis
|
||
Completed |
NCT02081963 -
Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis
|
Phase 4 | |
Completed |
NCT02883101 -
The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis
|
N/A | |
Completed |
NCT01792427 -
Mortality in Non-cystic Fibrosis Bronchiectasis
|
N/A | |
Recruiting |
NCT04278040 -
Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis
|
Phase 2 | |
Not yet recruiting |
NCT06352944 -
Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children
|
||
Recruiting |
NCT05860803 -
Breathing Training and Exercise Capacity in Non-CFB
|
N/A |